4.6 Review

Histone methyltransferase SMYD2: ubiquitous regulator of disease

期刊

CLINICAL EPIGENETICS
卷 11, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13148-019-0711-4

关键词

SMYD2; Methyltransferase; Nonhistone protein; Cardiovascular disease; Cancer

资金

  1. National Natural Science Foundation of China [81700249]
  2. Natural Science Foundation of Hubei Province [2018CFB734]
  3. Youth Talents Project of Hubei Health Commission [WJ2019Q043]

向作者/读者索取更多资源

SET (Suppressor of variegation, Enhancer of Zeste, Trithorax) and MYND (Myeloid-Nervy-DEAF1) domain-containing protein 2 (SMYD2) is a protein methyltransferase that methylates histone H3 at lysine 4 (H3K4) or lysine 36 (H3K36) and diverse nonhistone proteins. SMYD2 activity is required for normal organismal development and the regulation of a series of pathophysiological processes. Since aberrant SMYD2 expression and its dysfunction are often closely related to multiple diseases, SMYD2 is a promising candidate for the treatment of these diseases, such as cardiovascular disease and cancer. Here, we present an overview of the complex biology of SMYD2 and its family members and their context-dependent nature. Then, we discuss the discovery, structure, inhibitors, roles, and molecular mechanisms of SMYD2 in distinct diseases, with a focus on cardiovascular disease and cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据